For research teamsHelp me find a study
Study directory

Depression studies

Compare studies and check their requirements with the research team.

Back to overview
More filters: keywords, city, remote
262studies shown
Showing 61-72 of 262
Drug study icon
CompletedEUCTR 2015-002658-11

Long-term, open-label, flexible-dose, continuation extension study with vortioxetine in child and adolescent patients with Major Depressive Disorder (MDD) from 7 to 17 years of age

This EU register entry describes an interventional medicine trial, designed to assign participants a study treatment. The protocol sets out the treatment, eligibility criteria and assessments.

In France
Why is this study shown?

This study is directly about Depression.

DepressionDrugA study involving a medication or substance.
Countries
France, United Kingdom, Belgium, ...
Sponsor
H. Lundbeck A/S
Condition
Depression
View study
Drug study icon
Not recruitingEUCTR 2008-001580-11

A Randomized, Double-Blind, Parallel-Group, Placebo-Controlled, Fixed-Dose Study Comparing the Efficacy and Safety of 3 Doses of Lu AA21004 in Acute Treatment of Adults With Major Depressive Disorder

This EU register entry describes an interventional medicine trial, designed to assign participants a study treatment. The protocol sets out the treatment, eligibility criteria and assessments.

In France
Why is this study shown?

This study is directly about Depression.

DepressionDrug
Countries
France, United Kingdom, Germany, ...
Sponsor
Takeda Global Research & Development Centre (Europe) Ltd.
Condition
Depression
View study
Drug study icon
CompletedNCT06058039

Effects of Oral NMRA-335140 in people with Major Depressive Disorder

This study is completed in the United States, in France, in Bulgaria, .... It is testing Effects of Oral NMRA-335140 for depression.

In France
Why is this study shown?

This study is directly about Depression.

DepressionDrugFrom 18 Years to 65 Years
Countries
United States, France, Bulgaria, ...
Sponsor
Neumora Therapeutics, Inc.
Condition
Depression
View study
Other study type icon
Not recruitingISRCTN44737909

Effects of agomelatine on sleep electroencephalogram parameters compared to selective serotonin reuptake inhibitors in people with major depressive disorder: a six-week parallel group study versus comparator, followed by a optional treatment extension period up to six months

This study is not recruiting in Australia, in France, in the United Kingdom, .... It focuses on depression.

In France
Why is this study shown?

This study is directly about Depression.

DepressionOtherOver 18 Years
Countries
Australia, France, United Kingdom, ...
Sponsor
Institut de Recherches Internationales Servier (France)
Condition
Depression
View study
Other study type icon
Not recruitingISRCTN49376288

Efficacy of agomelatine given orally on rest/activity circadian rhythms in outpatients with major depressive disorder: a international study with parallel groups versus Selective Serotonin Reuptake Inhibitor (SSRI). Six-week treatment plus optional continuation for 18 weeks.

This study is not recruiting in France, in Austria, in Germany, .... It focuses on depression.

In France
Why is this study shown?

This study is directly about Depression.

DepressionOtherFrom 18 Years to 60 Years
Countries
France, Austria, Germany, ...
Sponsor
Institut de Recherches Internationales Servier (France)
Condition
Depression
View study
Drug study icon
CompletedEUCTR 2008-006492-71

A double-blind, efficacy and safety study of duloxetine versus placebo in the treatment of children and adolescents with major depressive disorder

This EU register entry describes an interventional medicine trial, designed to assign participants a study treatment. The protocol sets out the treatment, eligibility criteria and assessments.

In France
Why is this study shown?

This study is directly about Depression.

DepressionDrug
Countries
France, Estonia, Finland, ...
Sponsor
Eli Lilly and Company
Condition
Depression
View study
Drug study icon
CompletedEUCTR 2007-003312-65

Efficacy and safety of 2 doses of S 90098 (1 and 2mg/day), sublingual formulation for 8 weeks in out-patients with Major Depressive Disorder. An 8-week randomised, double-blind, fixed dose, interna...

This EU register entry describes an interventional medicine trial, designed to assign participants a study treatment. The protocol sets out the treatment, eligibility criteria and assessments.

In France
Why is this study shown?

This study is directly about Depression.

DepressionDrug
Countries
France, Czechia, Estonia, ...
Sponsor
Institut de Recherches Internationales Servier
Condition
Depression
View study
Drug study icon
CompletedEUCTR 2009-014045-92

Efficacy and safety of 3 doses (0.25, 0.5 and 1mg/day) of agomelatine sublingual administration over an 8-week treatment period, in out-patients with Major Depressive Disorder. An 8-week randomis...

This EU register entry describes an interventional medicine trial, designed to assign participants a study treatment. The protocol sets out the treatment, eligibility criteria and assessments.

In France
Why is this study shown?

This study is directly about Depression.

DepressionDrug
Countries
France, Czechia, Estonia, ...
Sponsor
Institut de Recherches Internationales Servier
Condition
Depression
View study
Drug study icon
CompletedEUCTR 2006-006540-54

Efficacy of agomelatine (25 to 50 mg/day) given orally on improvement of subjective sleep in patients with Major Depressive Disorder. A randomised, double-blind, flexible-dose international multice...

This EU register entry describes an interventional medicine trial, designed to assign participants a study treatment. The protocol sets out the treatment, eligibility criteria and assessments.

In France
Why is this study shown?

This study is directly about Depression.

DepressionDrug
Countries
France, United Kingdom
Sponsor
Institut de Recherches Internationales Servier
Condition
Depression
View study
Drug study icon
CompletedEUCTR 2006-003658-47

Exploratory study of the efficacy and safety of flexible doses of Milnacipran and Venlafaxine administered in out patients with Major Depressive Disorder.

This EU register entry describes an interventional medicine trial, designed to assign participants a study treatment. The protocol sets out the treatment, eligibility criteria and assessments.

In France
Why is this study shown?

This study is directly about Depression.

DepressionDrug
Countries
France
Sponsor
Pierre Fabre Médicament - IRPF
Condition
Depression
View study
Data coverage

Public registry coverage is progressing

HopeStage gathers information about mental health clinical trials from the public registries we currently index. We are progressively improving registry coverage, but this does not mean that every study in the world is already included.